Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Advances in the management of myelofibrosis.

Komrokji RS, Verstovsek S, Padron E, List AF.

Cancer Control. 2012 Oct;19(4 Suppl):4-15. Review.

PMID:
23042420
2.

Clarifying the use of ruxolitinib in patients with myelofibrosis.

Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO.

Oncology (Williston Park). 2013 Jul;27(7):706-14. Review. Erratum in: Oncology (Williston Park). 2013 Aug;27(8):737.

3.

Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Verstovsek S.

Postgrad Med. 2013 Jan;125(1):128-35. doi: 10.3810/pgm.2013.01.2628. Review.

4.

The evolving treatment paradigm in myelofibrosis.

Mesa RA.

Leuk Lymphoma. 2013 Feb;54(2):242-51. doi: 10.3109/10428194.2012.710905. Epub 2012 Aug 14. Review.

5.

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Vaddi K, Sarlis NJ, Gupta V.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Review.

PMID:
23051187
6.

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.

Martí-Carvajal AJ, Anand V, Solà I.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD010298. doi: 10.1002/14651858.CD010298.pub2. Review.

PMID:
25860512
7.

Clinical and laboratory features of myelofibrosis and limitations of current therapies.

Gregory SA, Mesa RA, Hoffman R, Shammo JM.

Clin Adv Hematol Oncol. 2011 Sep;9(9 Suppl 22):1-16.

PMID:
22362131
8.

Ruxolitinib: a new treatment option for myelofibrosis.

Ganetsky A.

Pharmacotherapy. 2013 Jan;33(1):84-92. doi: 10.1002/phar.1165. Review.

PMID:
23307549
9.

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM.

Intern Med J. 2017 Mar;47(3):262-268. doi: 10.1111/imj.13341.

PMID:
28260257
10.

Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?

Lancman G, Mascarenhas J.

Expert Rev Hematol. 2017 Jan;10(1):23-28. doi: 10.1080/17474086.2017.1264268. Epub 2016 Dec 5. Review.

PMID:
27882812
11.

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Bryan JC, Verstovsek S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26. Review.

12.

Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.

Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S.

J Hematol Oncol. 2012 Aug 1;5:43. doi: 10.1186/1756-8722-5-43. Review.

13.

How I treat myelofibrosis.

Cervantes F.

Blood. 2014 Oct 23;124(17):2635-42. doi: 10.1182/blood-2014-07-575373. Epub 2014 Sep 16. Erratum in: Blood. 2015 Aug 20;126(8):1048.

14.

Management of myelofibrosis: JAK inhibition and beyond.

Stahl M, Zeidan AM.

Expert Rev Hematol. 2017 May;10(5):459-477. doi: 10.1080/17474086.2017.1317590. Epub 2017 Apr 26. Review.

PMID:
28395559
15.

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.

Chen YY, Huang CE, Lee KD, Chen CC.

Hematology. 2016 Jan;21(1):3-9. doi: 10.1179/1607845415Y.0000000036. Epub 2015 Jul 27.

PMID:
26214121
16.

Emerging drugs for myelofibrosis.

Atallah E, Verstovsek S.

Expert Opin Emerg Drugs. 2012 Dec;17(4):555-70. doi: 10.1517/14728214.2012.748748. Review.

17.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.

Alchalby H, Kröger N.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S36-41. doi: 10.1016/j.clml.2014.06.012. Review.

PMID:
25486953
18.

Rationale for combination therapy in myelofibrosis.

Mascarenhas J.

Best Pract Res Clin Haematol. 2014 Jun;27(2):197-208. doi: 10.1016/j.beha.2014.07.009. Epub 2014 Jul 18. Review.

PMID:
25189730
19.

Myelofibrosis: an update on current pharmacotherapy and future directions.

Cervantes F, Martinez-Trillos A.

Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. Review.

PMID:
23514013
20.

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, Al-Ali HK.

Bone Marrow Transplant. 2014 Feb;49(2):179-84. doi: 10.1038/bmt.2013.173. Epub 2013 Dec 2.

PMID:
24292520

Supplemental Content

Support Center